FOLFIRINOX Side Effects Week by Week — A Caregiver's Reference

By Insight Swarm Research Team, Evidence-Based Research Review · Editorial standards overseen by Dr. Nikhil Joshi, MD, FRCPC

Short answer: FOLFIRINOX is given on a 2-week cycle (one infusion every 14 days). Side effects follow a predictable pattern within each cycle — the heaviest are nausea, diarrhea, and fatigue in days 1-5; neutropenia (low white-blood-cell count) and infection risk peak around days 7-10; and energy typically begins to return in days 11-14, just before the next dose. This piece walks through what to expect, what's worth a call to the oncology team, and what's a true emergency.

Why side-effect patterns matter for caregivers

FOLFIRINOX (a combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) is one of the most effective regimens for pancreatic ductal adenocarcinoma — and one of the most toxic. The PRODIGE 4/ACCORD 11 trial showed an overall-survival advantage over gemcitabine alone in metastatic disease, but at a cost of higher rates of diarrhea, neutropenia, and neuropathy (PMID: 21561347).

For a caregiver, knowing the pattern of side effects matters more than knowing the list of side effects. The list is overwhelming. The pattern is manageable.

Week 1 of the cycle (days 1-7)

Days 1-3 (infusion + the 46-hour 5-FU pump):

Acute oxaliplatin cold sensitivity — drinking cold water can feel like swallowing knives, touching cold metal can trigger tingling in the hands. This is usually short-lived (24-48 hours) and is the body's reaction to oxaliplatin, not a sign of permanent neuropathy.
Nausea — usually controlled by the anti-emetics given as part of the infusion. If nausea breaks through, call the oncology team rather than waiting for the next appointment.
Fatigue starting to build.

Days 3-5 (the pump comes off, but the chemo is still working):

Nausea typically worst on days 3-4 if it's going to be bad. Pre-medicate aggressively (anti-emetics on a schedule, not "as needed") for the first 2-3 cycles.
Diarrhea from irinotecan can start. The pattern is sometimes severe and sometimes mild — varies by individual. Loperamide is usually first-line; the oncology team will have a specific protocol.
Appetite often falls to its lowest point. Small, frequent, bland meals are easier than three "real" meals.

Days 5-7:

Energy may slowly start returning by day 6-7.
Mucositis (mouth sores) can appear around day 5-7 for some patients. Salt-and-baking-soda rinses several times a day help.

Week 2 of the cycle (days 8-14)

Days 7-10 — the neutropenia window:

White blood cell counts are typically at their lowest 7-10 days after infusion. This is when infection risk is highest.
Fever of 38.0°C (100.4°F) or higher during this window is an oncology emergency — not "wait and see." Most pancreatic-cancer caregivers should have the oncology team's after-hours phone number written down before the first cycle.
Fatigue often peaks alongside the neutropenia window. Many patients describe day 8-10 as the hardest.
Sometimes G-CSF (filgrastim/pegfilgrastim) injections are given to support white cell counts — talk to the oncology team about whether this is part of your regimen.

Days 11-14:

Energy begins to return.
This is often when patients feel best in the cycle — and when the next infusion is scheduled.
Some patients use this window for slightly more activity, social visits, or work, knowing the next cycle resets the clock.

Cumulative side effects (build over many cycles)

Some FOLFIRINOX side effects don't follow the cycle pattern — they build slowly:

Peripheral neuropathy from oxaliplatin is the big one. Numbness, tingling, or pain in the hands and feet that becomes persistent (not just cold-triggered). Once it crosses a certain threshold, it can become permanent. This is why oncologists sometimes reduce or remove oxaliplatin after a certain number of cycles — see PMID: 24430143 for the management framework.
Chemotherapy-induced fatigue can become a baseline new normal even on the "good" days of the cycle.
Liver enzyme changes that the oncology team will monitor on labs.

What to call the oncology team about

Don't wait for the next scheduled appointment for any of these:

Fever of 38.0°C / 100.4°F or higher
More than 4-6 loose stools in a day, or any blood in stool
Persistent vomiting (can't keep fluids down for 12+ hours)
New or worsening numbness/tingling that lasts more than a few days
New shortness of breath or chest pain
Calf pain, swelling, or redness (DVT can be a complication)
Confusion or sudden change in mental status

What you can do this week as a caregiver

Get the oncology team's after-hours phone number written on the fridge.
Buy or download a side-effect log — note severity 0-10 for nausea, diarrhea, fatigue, neuropathy each day. The pattern reveals itself within 2-3 cycles. Bring the log to every appointment.
Stock the pantry for the bad days, not the good days — bland, soft, easy. Crackers, broth, applesauce, eggs, plain rice.
Identify one person who can be on call for the neutropenia window (days 7-10) — the days you most need backup are predictable.

Limitations and second-opinion considerations

Every patient's pattern is somewhat different. Performance status, age, prior treatments, and genetic factors (UGT1A1 polymorphism affects irinotecan metabolism) all change the side-effect profile. If your loved one's side effects are dramatically more severe than this pattern, or if a single side effect is dominating quality of life, ask:

"Is modified FOLFIRINOX (lower-dose) an option?"
"Should we test for UGT1A1 polymorphism before continuing irinotecan?"
"At what point would we switch to gemcitabine + nab-paclitaxel?"

A high-volume pancreatic center can be a useful second opinion specifically on regimen choice if the local team is hesitant to modify.

Frequently Asked Questions

How many FOLFIRINOX cycles is typical?

For first-line metastatic pancreatic cancer, 8-12 cycles is typical, with continuation based on response and tolerance. For neoadjuvant treatment before surgery, 4-6 cycles is common. The exact number is individualized — your oncologist will decide based on imaging, CA 19-9 trends, and side-effect burden.

Is modified FOLFIRINOX as effective as full FOLFIRINOX?

Modified FOLFIRINOX (mFOLFIRINOX) uses lower doses of irinotecan and removes the 5-FU bolus, with the goal of preserving efficacy while reducing toxicity. Multiple studies suggest similar efficacy with meaningfully better tolerability ([PMID: 27621448](https://pubmed.ncbi.nlm.nih.gov/27621448/)). The choice depends on the patient's performance status and the treating oncologist's judgment.

When does oxaliplatin neuropathy become permanent?

There's no precise threshold, but persistent neuropathy that doesn't resolve between cycles, or neuropathy that interferes with daily function (buttoning a shirt, holding a fork), is a signal to discuss dose reduction or removing oxaliplatin from the regimen. Oncologists typically begin considering this around cycles 8-12, but earlier if symptoms are severe.

Can FOLFIRINOX cause hair loss?

FOLFIRINOX can cause thinning of hair, but full alopecia is less common than with some other regimens. Many patients keep most of their hair through treatment, with some thinning. This varies widely by person.

What should we do if the patient gets a fever during chemo?

A temperature of 38.0°C (100.4°F) or higher between cycles is a medical emergency — particularly during days 7-10 when white blood cell counts are lowest. Call the oncology after-hours line immediately. If they can't be reached, go directly to the emergency department and tell them the patient is on FOLFIRINOX and may be neutropenic. Do not wait until morning.

How do we know if FOLFIRINOX is working?

The oncology team looks at three things: imaging (CT or MRI every 2-3 months), CA 19-9 trend (if the tumor produces it — about 80% do), and clinical status (energy, symptoms, weight). One of these alone isn't conclusive; the combined picture is what matters. Ask at every restaging meeting: "How are all three indicators trending, and what would prompt a change in regimen?"